[sci.med.aids] Being Alive Newsletter - April 91 - part 1/2

gilbert@tcela.COM (Gilbert Cornilliet) (04/25/91)

Hi there!

This is a selection of articles (mostly medical) from
the April 1991 Being Alive Newsletter.

I am one of the editors of this Newsletter.
Comments, suggestions, critics, submission of articles, etc
are welcome. My E-mail address is gilbert@tce.com.

Please share this information with your friends.

Take care.

Gilbert.

======== TABLE OF CONTENTS ========

BEING ALIVE STATEMENT
HOW TO SUBSCRIBE TO THE BEING ALIVE NEWSLETTER
ABOUT THE BEING ALIVE NEWSLETTER

A REPORT ON THE FEBRUARY FDA ANTIVIRAL ADVISORY COMMITTEE MEETING
MEDICAL UPDATE - FEBRUARY 25, 1991
AZT RESISTANCE
CHOOSING THE BEST HOSPITAL FOR PATIENTS WITH AIDS 
FREE PLANE TICKETS, ACTIVISTS' SUPPORT GROUP AND OTHER THINGS
NUTRITION UPDATES
AIDS AND CHEMICAL DEPENDENCY
CLINICAL TRIALS AND YOUR PRIMARY HEALTH CARE PROVIDER
COMPOUD Q: TRICHOSANTHIN AND ITS CLINICAL APPLICATIONS 
TEENS REACH TEENS WITH HIV/AIDS INFORMATION
AIDS STORIES WANTED
LOCAL RESOURCES

================================================================

BEING ALIVE STATEMENT

Being Alive is an organization OF and FOR people with HIV/AIDS.

We understand the pain and the fear; how easy it is to hide, 
how difficult it can be to come to terms with this disease and 
reach out.

Being Alive is the means we have created to help us connect 
with each other, bring others like us out of isolation, and 
take charge of our lives, our care and our destiny.

Being Alive provides the following services to its members 
and the community:

Advocacy
HIV Fight Back! Library
Medical Update
Neighborhood Networks
Newsletter
Peer Counseling
Roommate Referral
Social Events
Speakers Bureau
Support Groups
Vital Information

TOGETHER, WE ARE MAKING A DIFFERENCE.

================================================================

HOW TO SUBSCRIBE TO THE BEING ALIVE NEWSLETTER

We are happy to provide the Being Alive Newsletter to people 
who cannot afford to purchase a subscription; however, we ask 
that anyone who can afford to subscribe, do so.

|__|    Enclosed is $12 for a six month subscription.

|__|    Enclosed is $20 for a one year subscription.

|__|    I cannot afford to pay for a subscription. 
        Please enter my free subscription.

|__|    Here is an additional donation to support Being Alive.

Name:                             Phone:
Address:
City:                             State:         Zip:

Please note that all names are kept confidential

4222 Santa Monica Blvd. Suite 105 - Los Angeles, California 90029

TOGETHER, WE ARE MAKING A DIFFERENCE.

================================================================

ABOUT THE BEING ALIVE NEWSLETTER

The Being Alive Newsletter is produced and published by Being 
Alive, People with HIV/AIDS Action Coalition, which is solely 
responsible for its content.

If you have articles you would like to submit to the Being 
Alive Newsletter or if you just want to help, please contact 
the Being Alive office during 
regular hours. 

Please note: Information and resources included with your 
Newsletter are for informational purposes only and do not 
constitute any endorsement or recommendation of, or for, any 
medical treatment or product by Being Alive, People with HIV/
AIDS Action Coalition. 

With regard to medical information, Being Alive recommends 
that any and all medical treatment you receive or engage in be 
discussed thoroughly and frankly with a competent, licensed, 
and fully AIDS-informed medical practitioner, preferably your 
personal physician. 

Being Alive and Being Alive Coping Skills Support Group are 
trademarks of Being Alive, People With HIV/AIDS Action 
Coalition, Los Angeles.

Opinions expressed in various articles in the Being Alive 
Newsletter are not necessarily those of Being Alive's 
membership.

Any individual's association with Being Alive or mention of an 
individual's name should not be, and is not, an indication of 
that person's health status. 

================================================================

A REPORT ON THE FEBRUARY FDA ANTIVIRAL ADVISORY COMMITTEE MEETING
by Jesse C. Dobson

 The FDA's Antiviral Advisory Committee met on February 13 and 
14 in Rockville, MD. The agenda for the first day of the 
meeting was to review data on the correlation between CD4 cell 
counts and survival and progression to disease in patients 
with HIV infection. 

DAY ONE: CD4 CELL COUNTS AS SURROGATE MARKERS

While not much is known about how HIV leads to the diseases 
commonly associated with AIDS, it is almost universally 
associated with a dramatic decline in numbers of CD4 cells. 
These cells play a pivotal role in the immune system. Healthy, 
uninfected individuals generally have counts between 
750-1200/mm3 of peripheral blood. When the numbers of these 
cells get low enough, typically less than 200, the 
opportunistic infections (OI's) associated with AIDS often 
begin to appear.

Historically, trials of anti-HIV drugs (like AZT, ddI, etc.) 
have used the occurrence and frequency of OI's or death as 
endpoints,or events indicating the drug's efficacy. Because 
HIV is a relatively slowly progressing disease, such events 
can take a long time to occur, especially in patients with 
high CD4 counts. This causes trials to necessarily be large 
(and therefore expensive) and slow, which results in both a 
long delay in finding desperately needed answers and a 
shifting of resources from other studies.

Because of this, researchers and patients alike have wanted a 
surrogate marker for HIV disease progression. Such a marker 
would allow trials to be quicker and smaller since theoretical 
differences between the drug being tested and the control 
group would show up quickly. CD4 counts have seemed an obvious 
surrogate marker to most people working with HIV disease. Many 
HIV doctors have used it to guide their clinical response to 
HIV for many years, often allowing them to determine the best 
use of therapies like AZT long before traditional clinical 
trials do. For example, when the Antiviral Advisory Committee 
recommended reducing the dose of AZT from 1200 to 600 mg/day 
in February of 1990, this dose and even lower doses had been 
standard clinical practice for over 18 months for many doctors 
with large HIV practices.

The FDA, however, has previously been unwilling to endorse 
this correlation between CD4 counts and disease progression as 
sufficient for approval of anti-HIV drugs. The meeting of the 
Antiviral Advisory Committee had the mandate for reviewing the 
data from several AZT trials to determine if such a 
correlation was scientifically justifiable, thereby allowing 
the agency to approve anti-HIV drugs on this basis.

DATA PRESENTED

The meeting began with a public forum, where several HIV 
community doctors and activists, including Dr. Marcus Conant 
of San Francisco and members of ACT UP/Golden Gate reminded 
the panel that such a recommendation was not purely scientific 
given the desperate need for better therapies. They argued 
that evidence of a correlation did not need to be ironclad to 
justify using CD4 counts and other markers like Beta 
2-microglobulin, an indirect immune system measure, for drug 
approval, as they are the best markers we have.

These were followed by data from large AZT studies, including 
those of the AIDS Clinical Trials Group (ACTG) and Burroughs 
Wellcome, the manufacturer of AZT. The data, which included 
some very sophisticated analyses by statisticians from 
Harvard, showed a strong relationship between CD4 counts and 
disease progression and survival. Particularly compelling were 
data from the National Cancer Institute (NCI) which showed 
that in a four year study of 55 patients with AIDS on 
AZT-based therapies only one death occurred in patients with 
over 50 T-cells. It is important to note, however, that this 
group of patients was receiving absolutely state-of-the-art 
medical care. 

The most important variable predicting health in all of the 
studies was the absolute CD4 count as opposed to the rate of 
CD4 change or the increase in CD4 due to the use of AZT. The 
bottom line was that increasing CD4 counts and keeping them 
high is the key to maintaining health. Another key variable in 
predicting progression was the age of the patient, with 
patients over 45 showing a significantly higher chance of 
progression.

CONCERNS VOICED

The main controversy of the day was a reluctance by some 
scientists to call CD4's a true surrogate marker. The strict 
definition of a surrogate marker requires that it be directly 
related biologically to the event that it replaces. Several 
scientists argued that CD4 count is only indirectly related to 
the occurrence of OI's. Also, it was observed in the analyses 
from Harvard that only about 30% of AZT's efficacy against 
disease progression could be accounted for by CD4 cell 
increases. This led to the concern that if studies become too 
dependent on looking for a rise in CD4, we miss real clinical 
benefits of drugs that don't give rise this rise but may 
reduce the risk of OI's anyway (DTC is such a drug). Dr.Larry 
Corey of the University of Washington at Seattle pointed out 
that any endpoint, including opportunistic infections and 
death are really a moving target, as improvements in 
treatments of OI's occur while trials are in progress and not 
uniformly at all centers. The panel agreed to call CD4 a 
partial surrogate marker and that clinical data needed to 
continue to be collected to prevent missing useful drugs.

FDA GUIDELINES SLOW IN COMING

Despite the unanimous support of CD4 for drug approval from 
the panel, until the FDA officially adopts guidelines on how 
to use them for drug approval the full benefit of such a 
marker cannot be realized. A key element of adopting this 
marker is that it could speed drug approval. This interests 
the pharmaceutical industry a great deal, as it would make 
drug development for AIDS cheaper and faster, which would 
allow them to recover their investment sooner (i.e., bigger 
profits). This may attract more drug companies to AIDS 
research, which would benefit everyone with HIV infection.

Until the FDA gives definitive, quantitative guidelines on how 
to use these markers, the drug companies are left facing the 
discretion of an agency that is itself reeling from the 
changes that have been wrought by this awesome epidemic and 
the formidable political force formed by those affected by it. 
Clear signals would give the companies a known goal and 
relieve the agency of a dizzying set of conflicting 
responsibilities. Unfortunately, the ways of bureaucrats 
change slowly. In a meeting with ACT UP/Golden Gate after the 
committee meeting, Carl Peck, the acting head of the Antiviral 
Division of the FDA, was unwilling to say when such guidelines 
would be available, or how quantitative they would be.

In a typical fashion, he has set up a task force to look into 
the issue. The task force hopes to have a draft of guidelines 
by April 1. Then after internal review, Peck  is considering 
publishing the guidelines in the Federal Register for public 
comment. This would add about another six months to the 
process. The earliest anticipated completion would be October. 
This would be roughly equivalent to 25,000 U.S. AIDS deaths. 
Meanwhile, New Drug Applications for ddI and ddC are 
anticipated to arrive at the agency in the next few months. If 
these guidelines were in place, fast approval would be easy. 
Lacking them, the approval process will be subjected to 
bureaucratic equivocation and charges of political pollution.

DAY 2: VETERANS ADMINISTRATION STUDY OF AZT

The second day focused on the results of a very large, 
completed study of AZT use in Veterans Administration (VA) 
hospitals. The study raised questions about the efficacy of 
AZT in early HIV disease, especially in some minority 
populations. The findings contradict those of earlier studies 
conducted in clinical research settings. Experts were quick to 
point out that small numbers of patients involved and 
imperfections in study design make the new findings 
questionable and that AZT should still be considered an option 
for early HIV therapy. They also agreed, however, that the 
findings warranted new studies specifically designed to answer 
the questions of whether the effectiveness of early anti-HIV 
therapy may be affected by either race or socioeconomic 
conditions.

The panel heard analyses of data from the VA study as well as 
from AIDS Clinical Trial Group (ACTG) studies and from 
Burroughs Wellcome, the manufacturer of AZT. None of the 
studies were designed specifically to look for the effects of 
race or socioeconomic conditions. The findings were based on 
retrospective analyses, which is considered to produce less 
reliable findings by most statisticians.

FINDINGS ON BLACKS AND HISPANICS

The VA study found that blacks and Hispanics, when lumped 
together to increase the number of events which improve 
statistical significance, were more likely to die from 
HIV-related causes when given AZT while their CD4 cells were 
greater than 200 than when they received therapy after falling 
below this number. They were also just as likely to progress 
to AIDS in both groups. This was in contrast to the 
non-Hispanic whites, who had significant benefit in 
progression to disease from early therapy and a small, but 
insignificant, improvement in survival.

Data from other ACTG studies showed that all races benefitted 
from early therapy equally, although numbers for blacks and 
Hispanics were small. Experts on the panel were unable to find 
any overriding problem with the VA study, even though issues 
of compliance, drug use and consistency of medical care were 
considered. Most on the panel were genuinely surprised by the 
results, as they saw no biological reason for the difference. 
Some pharmacokinetic data, which looked at how long AZT stayed 
in the blood, did find that AZT is cleared about 25% more 
quickly from blacks than from whites, which also surprised 
scientists. Again, the numbers were small in a study not 
designed to answer this question. This finding was not 
considered the reason for the results of the VA study since 
patients were given 1500 mg AZT/day, well in excess of the 
therapeutic dose of 300-500 mg/day from other studies.

No dose reductions were included in the study, unless a 
patient specifically showed toxicity to the drug. An ACTG 
study (016) showed that toxicity at 500 mg/day was not 
significantly less than the toxicity seen at the initial dose 
of 1500 mg/day. This goes against the conventional wisdom that 
lower doses of AZT are significantly less toxic. Overall 
toxicities in ACTG 016 were low, with no side effect seen in 
over 10% of the patients, including anemia.

Other interesting findings from the VA study were that blacks 
and Hispanics did not show the typical rise in CD4 counts 
after initiation of therapy and that their decline in CD4 
prior to therapy seemed to be slower than that found in 
whites. The minority patients also had a higher tendency to 
develop fatal opportunistic infections (OI's) with higher CD4 
counts than whites. No cases of dementia were seen in the 
early treatment group, indicating AZT may help prevent 
dementia.

COMMITTEE DELIBERATIONS ON AZT AND MINORITIES

After reviewing all the data, the committee did not think that 
the data were strong enough to call for changing the 
recommended use of AZT for people with less than 500 CD4 
cell/mm3. The doctors on the panel also generally agreed that 
they would not change their procedures in recommending the use 
of the drug, although most already caution their patients that 
the drug may not be a useful option for everyone. Most 
physicians said they would inform their patients of the VA 
results and let the patient decide.Dr. Howard Greaves, a 
consultant to and the only black on the panel, questioned the 
ethics of a large campaign promoting early intervention in 
light of the uncertainty raised by the study. When it was 
privately pointed out that the ads do not specifically 
recommend or even mention AZT, the panelists responded that in 
the information given when a person called the 800 number in 
the ad, AZT was specifically promoted.

The results led some activists attending to question whether 
AZT was useful in early therapy at all, and that what led to 
longer survival was management and prevention of OI's. This 
conclusion was dismissed by most experts, as the data from 
other studies strongly indicate that the drug is beneficial. 
One attendee also made the interesting observation that the VA 
study is the first large study not financed either directly or 
indirectly by the drug company. An independent study in Europe 
(the Concorde study) of AZT versus placebo in early disease 
has also yet to find a significant difference.

The panel then spent time deliberating on how to best evaluate 
the use of AZT and other HIV drugs in minorities. This led 
Alan Nowick, a member of the panel, to observe that all of 
those deliberating: the scientists, the regulators, the panel, 
the researchers, even the activists were all white, and that 
we all suffer for it. Indeed, there was one black doctor, 
especially invited to be on the panel instead of a regular 
member, and one other black and a few Hispanics and Asians in 
a audience of several hundred at a meeting about the effects 
of AZT in minorities.

(Jesse C. Dobson is a medical consultant to the National 
Association of People With AIDS.)

================================================================

MEDICAL UPDATE - FEBRUARY 25, 1991
presented by Mark Katz, M.D., and reported by Jim Stoecker

PCP IN HIV- ADULTS

An article in a recent New England Journal of Medicine 
reported on five elderly patients in New York City. These 
patients, all HIV-, came down with PCP even though there was 
no predisposing illness. No prior weakening of the immune 
system was apparent. The authors of the article cannot fully 
explain why PCP was found in these particular patients and 
draw no conclusions. This information, however, is intriguing 
and warrants further study.

MALE-TO-FEMALE SEXUAL TRANSMISSION OF HIV

In Africa, HIV infection has been evenly distributed between 
men and women. Male/female sexual intercourse has been the 
main means of transmission of HIV. A recent study in the 
Journal of Infectious Diseases affirms that the cofactors for 
male-to-female transmission of HIV in Africa are the same as 
those in Europe and North America. (Some sought to explain the 
African situation by positing more anal intercourse or by 
pointing to native blood rituals.) The authors point to the 
presence of genital ulcers, to Chlamydia infection and to the 
use of oral contraceptives. There do not appear to be 
cofactors unique to Africa.

RECOVERY OF HIV FROM SEMEN

A recent study looked for HIV in the semen of thirty-four 
infected men. Virus was recoverable in about a third of the 
semen samples tested. The presence of HIV, however, did not 
correlate with the stage of HIV disease or to the use of AZT 
therapy.

RHEUMATIC MANIFESTATIONS OF HIV INFECTION

Another symptom of HIV infection is painful and/or swollen 
joints. Researchers estimate that about a third of HIV+ people 
experience such symptoms. Usually these symptoms are 
transient, although some people actually come down with 
arthritis. Most rheumatic manifestations of HIV can be treated 
with non-steroid anti-inflammatory drugs (ibuprofen) or 
aspirin, although injectable corticosteroids are sometimes 
called for.

AZT CONSIDERATIONS

Two recent studies, one from Australia and the other from 
England, again affirm that AZT prolongs survival. Both 
studies, however, look at the length of time people survive 
with AZT vs. data from 5-6 years ago when AZT was generally 
unavailable. The researchers assume that AZT is the factor 
which explains the differing survival rates. The open question 
is whether other factors need to be considered.

Despite these and similar studies, some people resist taking 
AZT because they fear the drug's toxicity. What they need to 
keep in mind is that all AZT side effects are reversible. Once 
off the drug, side effects can be alleviated without, it 
appears, permanent damage.

People also continue to question whether AZT will really work 
for them. We have all heard the stories about AZT-resistant 
virus. What such resistance really means, however, is still 
unclear. What seems to be clear at this point is that the 
average person who takes AZT will be healthier for a longer 
time than the average person who does not take AZT.

DDI USE BY CHILDREN

A recent New England Journal of Medicine study reported on the 
use of DDI by forty-three children with symptomatic HIV 
disease. The drug was well tolerated. No neuropathy was 
observed, although two children did develop pancreatitis. A 
rise in CD4 counts was seen and the rise appeared to be 
sustained over time.

ROTATING ANTIVIRAL EXPERIMENT

Search Alliance in Los Angeles has inaugurated a study called 
RAVE (Rotating Antiviral Experiment). This study will take a 
close look at combination antiviral therapy, an approach that 
has been much talked about lately. Study subjects are in the 
200-500 T cell range. The protocol calls for a six week 
schedule: two weeks of AZT/DDI, then two weeks of DDI/DDC, 
then two weeks of AZT/DDC. The subjects then repeat this 
schedule for the length of the study. 

================================================================

AZT RESISTANCE
by Jeffrey M. Fricke, M.P.P.

Most researchers were not at all surprised several years ago 
when the phenomenon of AZT resistance was first documented. In 
fact, several investigational teams had been searching for 
zidovudine-resistant strains of HIV for some time before Dr. 
Brendan Larder first published the influential article "HIV 
with reduced sensitivity to zidovudine (AZT) isolated during 
prolonged therapy" in 1989. People with HIV infection, 
however, were understandably concerned. 

Dr. Larder detected a pattern in the measured sensitivity of 
viral isolates over time that suggested the development of AZT 
resistant strains of HIV. But he did not find this trend to be 
associated with a rise in viral p24 antigen concentration. 
Fortunately, he also did not find that patients with strains 
of resistant virus fared any worse than those without such 
strains. This important finding has been confirmed by many 
other studies. Furthermore, untreated patients have a poorer 
prognosis than those receiving zidovudine therapy, regardless 
of the presence of AZT-resistant strains of HIV.

Last year, Dr. Charles Boucher reported to the Sixth 
International Conference on AIDS that high level drug 
resistance develops noticeably faster in people with 
symptomatic HIV infection than in asymptomatic individuals.  
Dr. Douglas Richman also presented data indicating that in 
vitro resistance may appear at six months in patients with 
advanced disease and less than 200 CD4 cells/mm3. However, in 
asymptomatic or mildly symptomatic patients with over 500 CD4 
cells/mm3 treated for more than one year, only a small 
fraction showed any sign of resistant strains. 

Dr. Richman also reported in the August 1990 Journal of 
Acquired Immune Deficiency Syndromes that patients receiving 
lower doses of zidovudine at both early and late stages of 
disease did not develop resistance more readily than patients 
receiving higher doses of the drug. He further noted that the 
emergence of resistance results from both the mutation rate as 
well as the number of times the virus replicates. He concluded 
that "accumulating evidence indicates that virus replication 
progressively increases with disease progression as immunity 
diminishes."  Dr. Richman's findings indicated that early 
initiation of AZT therapy could lead to a longer period of 
effective treatment than if treatment is delayed. 

It is now known that AZT resistance results from multiple 
mutations occurring at the site of the gene which encodes 
reverse transcriptase. But the clinical significance of AZT 
resistance is not understood. Again, it is important to note 
that patients who have been treated with AZT and who have been 
found to carry resistant HIV strains do not appear to have a 
clinically worse profile. Nonetheless, the existence of 
mutant, AZT-resistant HIV stains is a continuing cause of 
concern. Fortunately, cross resistance has not yet been 
demonstrated with the anti-retroviral drugs dideoxyinosine 
(ddI) and dideoxycytosine (ddC). This has led to speculation 
that combination and/or alternating therapy approaches may be 
effective in preventing the emergence of drug resistant HIV-1 
mutant strains. 

There are many additional potential benefits associated with 
combination therapy approaches. For example, Dr. Tom Merrigan 
of Stanford University has reported that bone marrow toxicity 
was significantly reduced in alternating regimens with AZT and 
ddC than had been observed with continuous AZT therapy. The 
development of peripheral neuropathy remains a concern, 
however, and the optimal dosing schedules (including a 
drug-free period) have yet to be determined. Still other 
combination therapies, such as AZT, Recombinant Soluble CD4, 
and Recombinant Interferon-alpha A, have shown promise in the 
prevention of drug-resistant HIV-1 mutants.

It is also important to remember that it is possible for a 
given individual to carry many different strains of HIV. Some 
of these strains may have developed through mutation, still 
others may represent re-infection. While some resistant 
strains may develop, other strains may well exist which are 
kept in check through zidovudine therapy. Because the clinical 
significance of AZT resistance is unknown, a state-of-the-art 
conference sponsored by the National Institute of Allergy and 
Infectious Diseases published a report last year recommending 
further research. The report also stated "therapy with 
zidovudine is recommended for both symptomatic and 
asymptomatic HIV-infected individuals whose CD4 cell counts 
are below 500."  While AZT toxicities are well documented and 
many people require other anti-retroviral regimens, there is a 
general consensus that the known benefits of zidovudine 
therapy for most patients outweigh the theoretical concerns 
with AZT resistance.  

(Jeffrey M. Fricke is the Education Director at the UCLA AIDS 
Clinical Research Center.  He can be reached at (213) 
825-3594.Presentation of information here does not imply an 
endorsement of any action or treatment by the UCLA AIDS 
Clinical Research Center.)

================================================================

End of Being Alive Newsletter (April 1991 - part 1/2)